Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

In this expert-led case study, learn more about:

✓ Prolonging remission in AML

✓ Recommendations for upfront therapy

✓ Selecting between various maintenance strategies

 

In this exclusive case study, hear from David Sallman, MD, Moffitt Cancer Center, Tampa, FL, who introduces a case featuring a 64-year-old male with acute myeloid leukemia (AML). Dr Sallman discusses first-line treatment approaches, consolidation, and options for maintenance therapy, with the overall goal of prolonging remission in this patient.

Prior to completing this activity, how would you rate your confidence in selecting between maintenance therapy approaches for patients with AML?

Following the completion of this activity, how would you rate your confidence in selecting between maintenance therapy approaches for patients with AML?
I intend to change my clinical practice as a result of this activity

This educational activity has received independent medical education support from Bristol Myers Squibb. This supporter has no influence over the production of the content.

Explore more on our ‘Spotlight On: Prolonging Remission in AML‘ feature.

The content of VJHemOnc is intended for healthcare professionals